Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran*). Part I. absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers

Fertility and Sterility

Volumn 72, Issue 6, 1999, Pages 1001-1005

  Oberyé, Janine J L ^a   Mannaerts, Bernadette M J L ^a   Kleijn, Huub Jan ^a   Timmer, Cees J ^a  

^a Research and Development   (Netherlands)

Author keywords

Absolute bioavailability; Ganirelix; GnRH antagonist; Intravenous; Pharmacokinetics; Subcutaneous

Indexed keywords

GANIRELIX; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FEMALE INFERTILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; REFERENCE VALUES;

EID: 0032745044     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00413-6     Document Type: Article

References (12)

1. Conn P.M., Crowley W.F. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 45:1994;391-405.
2. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 13:1998;3023-3031.
3. Shah J., Monroe S., Wolfe L., LaFargue J., Pavlou S. Pharmacokinetics and pharmacodynamics of a novel GnRH antagonist (RS-26306) in humans. [abstract] Pharm Res. 8:(Suppl):1991;S249.
4. Rabinovici J., Rothman P., Monroe S.E., Nerenberg C., Jaffe R.B. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties studies in post-menopausal women . J Clin Endocrinol Metab. 75:1992;1220-1225.
5. Nelson L.R., Fuijimoto V.Y., Jaffe R.B., Monroe S.E. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril. 63:1995;963-969.
6. Fuijimoto V.Y., Monroe S.E., Nelson L.R., Downey D., Jaffe R.B. Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (ganirelix) administered by intranasal spray. Fertil Steril. 67:1997;469-473.
7. Nerenberg C., LaFargue J., Gee C., Chu F., Wolfe L., Chan R., et al. Radioimmunoassay of ganirelix in plasma or serum. J Immunoassay. 14:1993;191-207.
8. Hermann R., Romeis P., Schneider E., Ellers-Lenz B., Ruus P., Reissmann T., et al. Pharmacokinetics and absolute bioavailability of the LHRH-antagonist cetrorelix in healthy male and female subjects. [abstract] Eur J Clin Pharmacol. 40:1995;A153.
9. Pavlou S.N., Wakefield G., Schlechter N.L., Lindner J., Souza K.H., Kamilaris C.T., et al. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing antagonist in normal men. J Clin Endocrinol Metab. 68:1989;446-454.
10. Duijkers I.J.M., Klipping C., Willemsen W.N.P., Krone D., Schneider E., Niebch G., et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist cetrorelix in healthy female volunteers. Hum Reprod. 13:1998;2392-2398.
11. Behre H.M., Klein B., Steinmeyer E., McGregor G.P., Voigt K., Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab. 75:1992;393-398.
12. Morgan J.E., O'Neil C.E., Coy D.H., Hocart S.J., Nekola M.V. Antagonistic analogs of luteinizing hormone-releasing hormone are mast cell secretagogues. Int Arch Allergy Appl Immunol. 80:1986;70-75.